Search

everythinglearnresearchcommunity

for

Search:↓

Microneedling is preferred over laser therapy for hair loss because it is cheaper and reportedly effective, especially with minoxidil. Laser therapy is seen as costly and less effective.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. Users find ChatGPT a helpful tool for researching these treatments.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

Hair loss is linked to DHT, with treatments like finasteride and minoxidil being common but not definitive. Economic interests influence research, and there is potential for new treatments like PP405 and RU58841.

Microneedling regimens for hair loss, with users discussing needle lengths and frequencies. One user reports noticeable improvement at the crown using 1mm weekly, while another uses Keto shampoo with dermastamping.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.

The conversation discusses using magnesium oil and microneedling to promote hair growth, alongside finasteride, due to financial constraints preventing the use of minoxidil. Another suggestion includes using a certilizine solution for hair health.

The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It highlights a study suggesting that sulforaphane may reduce DHT levels and promote hair growth in mice.

A 48-year-old who had been thinning since 25 and reached NW4-5 baldness saw no improvement with 1mg/day finasteride and 5% minoxidil twice a day after 8 months. After copying another person's routine, they now use 0.5mg finasteride, ketoconazole shampoo weekly, daily microneedling with 0.5mm and 1mm once a week, and apply minoxidil twice daily, resulting in baby hairs on their bald spot and temples after three months.

A video suggests 0.6mm microneedling is more effective for hair regrowth than 1.2mm, as it causes less trauma to stem cells. People commonly believe 1.5mm is best, but this may vary based on individual factors.

Creatine may increase DHT levels, potentially affecting hair loss, but evidence is mostly anecdotal. A study to explore this was withdrawn due to funding issues.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

The conversation is about the effectiveness of peptides for hair loss and the user considering using GHK-Cu, CJC-1295, and BPC-157 for treatment.

Microneedling and tretinoin may enhance minoxidil absorption for hair loss, but evidence on their effectiveness is limited. Iron supplements and broccoli sprouts are suggested for enzyme activation, but their impact on hair is unclear.

Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

The conversation discusses RU58841, a compound for hair loss treatment, which was found to be effective in a 6-month trial but was not pursued due to financial issues or marketability concerns, not safety. Some users are considering crowdfunding to release the research data, while others discuss personal experiences and safety concerns with RU58841.

Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.

The conversation discusses using different concentrations of topical treatments for hair loss, specifically Minoxidil, Finasteride, Dutasteride, and Tretinoin. The user is considering higher concentrations after previous treatments were ineffective.

Hair loss treatments like Minoxidil, finasteride, and potential mRNA therapies are discussed. There is skepticism about targeting specific genes due to the complex genetic nature of hair loss.

Microneedling promotes hair growth by increasing circulation and collagen production, with gains potentially lasting longer than those from minoxidil. Some users report sustained results after stopping microneedling, unlike with minoxidil and finasteride.

Considering adding Low Level Laser Therapy (LLLT) to a hair loss prevention regimen; discussing the effectiveness of LLLT, and evaluating double-blind random-controlled trials that have been conducted on laser combs.

The conversation discusses alternative hair loss treatments beyond the commonly used Minoxidil and Finasteride. One user is trying diclofenac gel, caffeine + antioxidant serum, finasteride, ketoconazole shampoo, and has stopped using Minoxidil due to ineffectiveness, while another user has adopted lifestyle changes like exercise, diet, stress reduction, and topical caffeine, along with scalp massages and microneedling.

The conversation discusses the use of microneedling for hair loss, with concerns about potential long-term effects like fibrosis and scarring. Users share experiences and opinions on combining microneedling with treatments like minoxidil and finasteride, but there is uncertainty about the long-term safety and efficacy.

The post discusses microneedling for hair regrowth, with the original poster seeking experiences of those who didn't see positive effects. A reply suggests that while microneedling doesn't guarantee hair regrowth, it increases the chances if done correctly.

Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.

Oral minoxidil is considered effective for hair growth, and some users combine it with microneedling despite mixed opinions on its additional benefits. Concerns about microneedling include potential scarring and lack of conclusive evidence on its effectiveness when used with oral treatments.

User reports hair loss improvement using finasteride, minoxidil, and microneedling. Others praise progress and share experiences.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.